Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00190697
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : May 25, 2007
Information provided by:
Eli Lilly and Company

Brief Summary:
Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this "roll-over" study if they had exhibited clinical benefit from treatment and wished to continue on treatment. Patients were monitored for safety.

Condition or disease Intervention/treatment Phase
Breast Cancer Endometrial Cancer Ovarian Cancer Drug: arzoxifene Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer
Study Start Date : January 2001
Actual Study Completion Date : April 2007

Primary Outcome Measures :
  1. To allow continued treatment of patients who exhibited clinical benefit from arzoxifene

Secondary Outcome Measures :
  1. To collect long-term safety data on arzoxifene use in advanced cancer patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participation in a clinical trial of LY353381 that has met its main safety and efficacy objectives, and could otherwise close.
  • Evidence of continuing benefit with LY353381 (eg. complete response, partial response or stable disease with no symptomatic or clinical evidence of disease progression).
  • Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia).
  • Written informed consent from patient.
  • Childbearing potential either terminated by surgery, radiation, menopause, or attenuated by use of an intra-uterine contraceptive device or barrier method during and for 3 months after the trial.

Exclusion Criteria:

  • No concurrent systemic therapy (immunotherapy, hormone therapy or chemotherapy) for cancer. Palliative radiotherapy is allowed (eg, for pain) as long as there is no evidence of disease progression. Investigational agents, other than LY353381, within the 4 weeks prior to this study enrollment and other SERMs are also not permitted.
  • No concurrent use of oral contraceptives, GnRH agonists, or coumarin (warfarin).
  • No serious concomitant systemic disorders incompatible with the study (at the discretion of investigator), including predisposition to thromboembolic disorder.
  • Must not be pregnant or breast-feeding.
  • Must not have a gap in treatment of more than 4 weeks between previous LY353381 study and enrollment in current study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00190697

Layout table for location information
United States, Texas
For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician
Houston, Texas, United States, 77030
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-285-4559 (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Additional Information:
Layout table for additonal information Identifier: NCT00190697    
Other Study ID Numbers: 5234
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: May 25, 2007
Last Verified: May 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Neoplasms
Uterine Diseases